COMP <GO>
TECH vs EXEL // FORWARD P/E MULTIPLE
Bio-Techne Corp (NASDAQ) VS. Exelixis Inc. (NASDAQ) • 15-METRIC TALLY: TECH 1
— EXEL 13
▲ FORWARD P/E MULTIPLE LEADER: EXEL
LAST: $72.67 (+0.01%) • MKT CAP: $11.39B
forward-pe
140.0x
LAST: $70.13 (+1.07%) • MKT CAP: $16.93B
forward-pe
19.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TECH VS. EXEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TECH | EXEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 64.80% | 96.00% | -31.20 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | 35.10% | -31.70 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 91.3x | 18.4x | +72.90 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 2.25% | 5.34% | -3.09 | EXEL | /fcf-yield <GO> |
| Operating Margin | 8.40% | 37.60% | -29.20 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 6.00% | 33.70% | -27.70 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 7.00% | -1.80 | EXEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.44% | 0.00% | +0.44 | TECH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.12 | 16.64 | -9.52 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 70.9 | -14.80 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.96 | -0.08 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 140.0x | 19.5x | +120.50 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.39B | $16.93B | -$5.54B | EXEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TECH REV | EXEL REV | TECH GROSS % | EXEL GROSS % | TECH FCF | EXEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.22B | $2.32B | 64.8% | 96.4% | $256.6M | $875.8M |
| FY 2024 | $1.16B | $2.17B | 66.4% | 96.5% | $236.1M | $671.5M |
| FY 2023 | $1.14B | $1.83B | — | — | $203.2M | $251.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TECH // BETA 0.88
EXEL // BETA 0.96